Paper Details

  1. Home
  2. Paper Details

First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center.

Author: ChenHui-Qing, SongJi-Wen, WangBin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pazopanib, a multi-kinase inhibitor, is effective as first-line therapy for metastatic renal cell carcinoma (mRCC) in a Chinese population. It achieved an objective response rate (ORR) of 34.5% and disease control rate (DCR) of 75.9%, with a median progression-free survival (PFS) of 10.1 months. The most common side effects were fatigue, hand-foot syndrome, and elevated ALT/AST.
Paper Details　
Original Abstract of the Article :
The response to pazopanib in patients with metastatic renal cell carcinoma (mRCC) has been found to differ in Western and Eastern populations. Here, we analyzed the efficacy and side effects of pazopanib as first-line therapy in 31 consecutive patients with mRCC who were treated at a single Chinese ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658599/

データ提供：米国国立医学図書館（NLM）

Pazopanib as First-Line Treatment for Metastatic Renal Cell Carcinoma

This research investigates the real-world efficacy and safety of pazopanib as a first-line treatment for metastatic renal cell carcinoma (mRCC) in a Chinese population. The study retrospectively analyzes the outcomes of patients treated with pazopanib at a single center, providing insights into the drug's effectiveness and tolerability in this specific patient cohort.

Pazopanib in the Desert of mRCC

The study suggests that pazopanib is a viable first-line treatment option for mRCC in Chinese patients. The results demonstrate a significant objective response rate and disease control rate, with a median progression-free survival of 10.1 months. While the study acknowledges that further research is needed to confirm these findings, it provides valuable real-world data on the effectiveness of pazopanib in a specific patient population.

mRCC: Navigating the Desert of Metastasis

Metastatic renal cell carcinoma (mRCC) is a challenging condition, often requiring complex and aggressive treatment strategies. This research explores the potential of pazopanib as a first-line treatment option, offering a potential oasis in the midst of this challenging landscape. The study's findings provide insights into the efficacy and safety of pazopanib in a real-world setting, offering valuable guidance for clinicians treating mRCC.

Dr. Camel's Conclusion

This research is like a caravan traversing the desert of mRCC, seeking effective treatment options for patients. The study's findings suggest that pazopanib may hold promise as a first-line therapy for mRCC in Chinese patients, offering a beacon of hope in the midst of this challenging journey.
Date :
  1. Date Completed n.d.
  2. Date Revised 2020-11-17
Further Info :

Pubmed ID

33192500

DOI: Digital Object Identifier

PMC7658599

Related Literature

Article Analysis
・Side Effects of pazopanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.